Lenz Therapeutics Releases 2026 First Quarter Results

Published on May 12, 2026
SAN DIEGO, Calif.—Lenz Therapeutics, Inc. (Nasdaq: LENZ), a pharmaceutical company focused on the commercialization of VIZZ  (aceclidine ophthalmologic solution) 1.44%, an FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, yesterday announced its first quarter 2026 financial results. The company reported total revenue of $1.9 million in Q1, with VIZZ product sales accounting for $1.7 million of revenue. During this period, product sales were bolstered by nearly 25,000 paid prescriptions for VIZZ, reflecting a 19 percent increase compared with the fourth quarter of 2025, the announcement said.
Continue reading on website
Other news

The National Average for Gross Revenue at ECP Locations Decreased for the Month of April, Jobson’s Latest Practice Performance Tracker Shows

May 12, 2026
NEWARK, N.J.—The national average for gross revenue at ECP locations decreased last month, April 2026, when compared with the previous month, at a rate of -7 index points. That places gross revenue at a level -1 index point below where it was at this point in time (April) when compared with last year (2025), 8 points above the same period in 2024, 26 points above 2023, 29 points above 2022, 30 poi

Safilo Group Inks Deal to Acquire SPY+ and Serengeti

May 12, 2026
PADUA, Italy—Safilo Group announced yesterday that it has signed a share and asset purchase agreement (SAPA) with Bollé Brands for the acquisition of SPY+ and Serengeti. The news comes on the heels of an announcement from Safilo Group in April that it had signed an exclusivity agreement with Bollé Brands aimed at the acquisition of the two U.S. brands, which operate in the sports/outdoor and high-